Rethinking cancer vaccines through the tumour immunopeptidome
Direct identification of specific tumour-derived HLA-bound peptide targets is enabling the development of personalised immunotherapy strategies
Treatment duration of immunotherapy combination does not impact on disease-free survival in dMMR colon cancer
An ATOMIC study pre-planned exploratory analysis reports no DFS benefit with the addition of immunotherapy in patients receiving fewer than six cycles of chemotherapy
Is there a role for intensification immunotherapy in patients with locally advanced cervical cancer?
Immunotherapy is optimising outcomes in LACC, with durable responses and long-term survival, especially in those with immune activated or ‘hot’ tumours
First-line dual targeting combination shows encouraging, durable responses in triple-negative breast cancer
A manageable safety profile was also reported for pumitamig plus the antibody-drug conjugate DB-1305/BNT325 in an early-phase study
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
Meta-analysis shows non-inferiority of later versus earlier immunotherapy administration in lung cancer
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents
Cancer Research
Rethinking the immunotherapy paradigm for a sustainable and equal cancer care
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access